Chinese Drugmaker Stocks Slide Amid Fears of U.S. Regulatory Action
Shares of major Chinese pharmaceutical companies declined sharply this week following reports of a potential regulatory clampdown by U.S. authorities. The sell-off was triggered by growing concerns over increased scrutiny of Chinese drug exports and supply chain practices. Investors reacted to speculation that Washington may impose tighter controls on imports of active pharmaceutical ingredients (APIs) […]
Continue Reading